CompanyGraph
A molecule becomes a treatment only when evidence, manufacturing, clinical practice, payment, and patient access remain connected across its life.
A medicine starts as uncertainty
A pharmaceutical company does not begin with a product that can be shipped. It begins with a biological hypothesis and a large number of ways to be wrong. A candidate must be made consistently, tested in stages, shown to have an acceptable balance of benefit and risk, reviewed for a defined use, and manufactured in a form that clinicians can prescribe and patients can receive. A research budget is therefore not a supply of treatments. It is money held against uncertain future routes.
Merck's history includes statins, vaccines, oncology drugs, and animal-health products, but the same physical boundary persists: scientific plausibility is not clinical function. A promising molecule can fail because it is unsafe, ineffective in the target population, difficult to formulate, impossible to manufacture at scale, or unable to reach patients through the payment system.
Trials and approval create a defined route
Clinical trials observe selected people under specified protocols. A regulator then evaluates a defined application, indication, formulation, and evidence set. FDA's drug-development and post-market guidance distinguishes approval from the continuing monitoring of safety after a product is used more broadly. Approval establishes that a regulator found the evidence sufficient for the reviewed use; it does not establish that every patient will respond or that every later condition has been observed.
Manufacturing adds another qualification. A plant must make the approved product with the right identity, strength, purity, process controls, and release testing. A batch record, a shipment, and a prescription each observe a different boundary. A sales number can show that money changed hands, but it cannot show whether a dose reached the right patient or produced the intended outcome.
Keytruda becomes a franchise
Pembrolizumab, sold as Keytruda, expanded across many cancer indications as clinical evidence accumulated. Each new indication can enlarge the treated population and strengthen the evidence history, but it also joins more patient groups, prescribers, manufacturing demand, and reimbursement decisions to the same molecule and exclusivity calendar.
Merck's 2025 Form 10-K reports that Keytruda represented 49% of total company sales in 2025. The filing anticipates U.S. biosimilar competition could begin in December 2028, while describing a separate European timing. The figure establishes concentration and a disclosed legal timetable; it does not tell us how quickly physicians, payers, patients, and manufacturers will change their behavior.
That is the unusual strength and vulnerability of a platform franchise. Evidence accumulated across indications helps the drug fit many clinical decisions. The same breadth means that a change in exclusivity can affect a large connected set of treatments at once.
Manufacturing and access are separate boundaries
Even an approved treatment needs factories, raw materials, sterile or controlled processes, quality testing, packaging, wholesalers, pharmacies, clinicians, and a patient who can obtain it. Capacity at one site does not establish supply at every hospital. A formulation change can require new evidence or manufacturing work. A reimbursement restriction can make a clinically appropriate treatment unavailable to the person who needs it.
Money arrives at different points. Merck funds discovery and trials before approval, builds or contracts manufacturing before demand is certain, and carries inventory and quality obligations before payment is collected. Hospitals and payers then determine whether a prescription becomes an administered dose. A profitable product can coexist with a patient-specific access failure because revenue, stock, coverage, and treatment are different observations.
The patent clock changes the financing problem
Patent and regulatory exclusivity can support the revenue that pays for future research, but the legal clock does not make replacement automatic. A biosimilar manufacturer still needs a qualified process, regulatory submission, capacity, and a commercial route through physicians and payers. The originator still needs to decide whether to invest in new formulations, combinations, indications, or entirely different mechanisms.
For Merck, the timing matters because Keytruda's sales are large enough to change the scale of the replacement problem. The question is not whether a single candidate can be called a successor. It is whether several candidates, manufacturing routes, acquisitions, and indications can supply enough clinical function and cash flow as the franchise changes.
Pipeline and Animal Health preserve different options
Merck's pipeline contains programs at different stages and in different therapeutic areas. A candidate in early research, a late-stage trial, a regulatory review, and a launched product are not interchangeable assets. Each has a different probability of reaching patients, a different cash requirement, and a different remaining time before competitors can respond.
Animal Health is another route, not a substitute for human oncology. It can provide cash flow and scientific or commercial diversity on a different disease and regulatory cycle. It cannot replace Keytruda's human-treatment function or remove the need for successful human clinical development. Diversification changes the set of options; it does not erase the largest dependency.
Feedback continues after launch
Post-market reports, safety signals, claims data, clinical practice, and patient outcomes can reveal problems or uses that pre-market studies did not fully resolve. A signal is not automatically a proven cause, and a report is not automatically a correction. The useful feedback path requires product identity, lot or formulation information, clinical context, and an organization with authority and money to investigate and change manufacturing, labeling, trial design, or practice.
This is why the Vioxx withdrawal remains more than a historical event: it shows how a safety signal can force a company to change the route by which evidence and commercial decisions meet. The same system that makes a blockbuster profitable must also preserve the ability to stop, investigate, and alter it.
What a complete pharmaceutical route preserves
Merck's durable capability is not simply research talent or a patent portfolio. It is the maintained connection from biological idea to qualified batch, evidence-based use, payment, patient access, and feedback. Keytruda concentration makes that connection visible because one franchise has become a large share of the company's sales while its legal protection approaches a known transition.
A patent cliff is therefore neither a guaranteed collapse nor an ordinary product launch. It is a change in the conditions under which treatment, revenue, manufacturing, and future research must be connected again. The next result depends on what evidence, money, capacity, and authority remain available when each earlier route changes.